Published:
Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call
LYON, France - (BUSINESS WIRE) - Flamel Technologies (Nasdaq: FLML) expects to release its
financial results for the third quarter of 2009 the morning of November
16th, before the market opening. A conference call to discuss the
results has been scheduled for Monday, November 16th, at 8:30
AM (Eastern). A question and answer period is expected to follow the
discussion of results.
To participate in the conference call, investors in the US and Canada
are invited to dial 1-800-860-2442. International callers are invited to
call 1-412-858-4600. The Conference ID number is # 435349. The
conference call webcast may be accessed at www.flamel.com.
Flamel Technologies, S.A. is a biopharmaceutical company principally
engaged in the development of two unique polymer-based delivery
technologies for medical applications. Micropump is a
controlled release and taste-masking technology for the oral
administration of small molecule drugs; it is the intellectual platform
licensed by Glaxo SmithKline for the development of Coreg CR . Flamel's
Medusa technology is designed to deliver controlled-release
formulations of therapeutic proteins and peptides.
This document contains a number of matters, particularly as related
to financial projections and the status of various research projects and
technology platforms, that constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
The presentation reflects the current view of management with respect
to future events and is subject to risks and uncertainties that could
cause actual results to differ materially from those contemplated in
such forward-looking statements.
These risks include risks that products in the development stage may
not achieve scientific objectives or milestones or meet stringent
regulatory requirements, uncertainties regarding market acceptance of
products in development, the impact of competitive products and pricing,
and the risks associated with Flamel's reliance on outside parties and
key strategic alliances.
These and other risks are described more fully in Flamel's Annual
Report on the Securities and Exchange Commission Form 20-F for the year
ended December 31, 2008.
Flamel Technologies
Charles Marlio, Director of Strategic Planning
and Investor Relations
tel: (+) 33 (0)4 7278 3434
fax:
(+) 33 (0)4 7278 3435
Marlio@flamel.com
Copyright © 2009, Business Wire, Inc., All rights reserved.
Copyright © 2009, NewsBlaze,
Daily NewsTags: Pharmaceuticals, Business wire, Biotechnology, , district of columbia, Health
Search News
Daily News
